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Background: The aim of this study was to investigate differences in HIV disease progression in patients infected 
with HIV subtype B with a GPGR motif in the V3 loop region (B-GPGR) versus the Brazilian subtype B variant 
with a GWGR motif (B’-GWGR). 
Materials and Methods: Patients were enrolled in an ongoing cohort study at the University of SBo Paulo Derma- 
tology Clinic in Sao Paulo, Brazil. V3 serology was performed by enzyme immunoassay with peptides representing 
two HIV subtype B strains, MN and SF2, and two Brazilian variant B’-GWGR strains. The incidence of AIDS- 
defining events was calculated, and Cox proportional hazards regression was used to estimate adjusted risk ratios. 
Results: Of the samples from 114 patients studied, 23 (20%) were classified as B’-GWGR motif, and 91 (80%) as 
B-GPGR motif. Patients with T CD4+ cell counts less than 200 cells/mm3 or 200-400 cells/mm3 experienced an 
increased incidence of AIDS-defining events compared with patients who entered the cohort withT CD4’ cell counts 
greater than 400 cells/mm3. In a proportional hazard model including age, gender, T CD4’ cell count at entry into 
the cohort, and V3 serology, GWGR reactivity was associated with a decreased hazard rate for presenting an AIDS- 
defining condition during follow-up. Three patients in the group with GPGR serology died after experiencing an 
AIDS-defining event. None of the patients with GWGR serology died during follow-up. 
Discussion: Survival analysis showed that patients infected with the Brazilian subtype B variant with a GWGR motif 
in the V3 loop had lower risk, adjusted for initial CD4’ cell count, of AIDS-defining events than patients infected 
with subtype B-GPGR strains. 
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INTRODUCTION 
Viral characteristics have been shown to influence the 
pathogenesis of human immunodeficiency virus (HIV) 
infection or progression to acquired immune deficiency 
syndrome (AIDS). For example, genetic alterations, such 
as nef gene deletion, were shown to be associated with 
a lower rate of depletion of T CD4+ cells during follow- 
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up,’ and HIV-2 seems to be less pathogenic than HIV- 
1.2 These findings may be related to the capacity of the 
virus to induce syncitia, differences in coreceptor usage, 
or other mechanisms.3 
HIV-l genetic variation has been assessed using 
molecular biology, mainly through PCR/heteroduplex 
gel mobility protocols. These approaches, in addition to 
DNA sequencing data, have demonstrated that HIV-l 
may be classified into at least 10 different genotypes, 
designated A-J, based on the sequence of the envelope 
gene.4 In Brazil, the majority of HIV-1 infections are 
subtype B, followed by F and the newly emerging sub- 
types C and D in southern and southeastern regions of 
the country.5,6 The city of SBo Paulo has the highest 
number of AIDS cases of any city in Brazil, and the state 
of S&o Paulo accounts for as much as 40% of all AIDS 
cases reported in Brazil during the last 20 years.7 There 
are at least three different genetic HIV-l subtypes (B, 
F and C) co-circulating in the city and state of Sao Paulo, 
with subtype B accounting for more than 90% of infec- 
tions.5s 
Complementary to genotype classification, anti- 
bodies against the V3 loop region, an important target 
for humoral and cellular immune responses, have been 
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used to serologically discriminate antigenic subtypes4 
Two antigenically distinct variants of HIV-l subtype B 
have been described, mainly in Thailand and Brazil.9,‘o 
Although the V3 loop region is highly divergent in 
Brazil, especially in the 1.5 amino acids of the tip, two 
genetically and antigenically distinct strains of subtype 
B account for the majority of HIV-l subtype B infections: 
one strain has the GPGR motif in the crown of the V3 
loop region, similar to US/European isolates (B-GPGR), 
whereas the other has a GWGR motif that is unique to 
Brazil and Latin America (B’-GWGR).‘&‘” It has been 
shown that the Brazilian variant, B’-GWGR, is widely 
disseminated and represents almost half of the HIV-l- 
infected subtype B population in some areas.14.i5 A pre- 
vious report suggested that the rate of progression 
to AIDS was lower among B’-GWGR-infected than 
among B-GPGR-infected patients before and after the 
initiation of antiretroviral therapy (ART).i6 Using a 
different cohort of HIV-l-infected Brazilian patients, 
the effect of differences between the two strain types on 
the rate of AIDS progression can be examined during 
the natural history of HIV, prior to initiation of highly 
active antiretroviral therapy (HAART). 
We previously described a modified enzyme im- 
munoassay (EIA) based on V3 reactivity to discriminate 
between subtype B GPGR and B-variant B’-GWGR.14%i5 
The objective of the current study was to compare 
disease outcomes prior to the initiation of ART in 
patients infected with the B-GPGR strain or B’-GWGR 
strain. 
MATERIALS AND METHODS 
The study was conducted at the ambulatory service of 
the secondary immunodeficiency clinic of Hospital das 
Clinicas, the largest teaching and research hospital in 
Latin America. In total, 219 HIV-l-infected subjects 
were enrolled in a cohort to study the natural history 
of HIV infection in Sao Paulo.17 The first cases were 
recruited in October 1987 and the last in December 
2000. Demographic and clinical data were obtained 
from clinical charts or direct interview. The Ethical 
Committee of Hospital das Clinicas, University of Sao 
Paulo (HCFMUSP), approved the study protocol. 
V3 serology was done in accordance with previously 
published assays.i4J5 Briefly, biotinylated peptides based 
on the V3 loop consensus sequences from two subtype 
B strains, MN and SF2, and two synthetic peptides based 
on the consensus sequence of the Brazilian variant 
subtype B strain were captured in avidin-coated 96-well 
plates. Serial four-fold dilutions of test sera were added. 
Bound antibody was detected with a peroxidase-labeled 
anti-human IgG and TMB substrate. The plates were 
read at 450 nm, and the endpoint titers were inter- 
polated from the linear portion of the titration curve, 
yielding a mean absorbance of 0.5 optical density units. 
For indeterminate serum samples, an inhibition assay 
was performed. In this assay, the patient sera were pre- 
incubated with individual synthetic GWGR or GPGR 
peptides, and the percentage inhibition of antibody 
binding to coated wells was calculated for GWGR- and 
GPGR-specific peptides. Inhibition greater than 50% 
was used as the cutoff for defining V3 serotype for these 
samples. The use of V3 serology to discriminate subtype 
B GPGR and GWGR strains in Brazil has previously 
been validated by DNA sequence-typing.15 
Definitions and statistical methods 
AIDS-defining events were determined in accordance 
with guidelines of the Centers for Disease Control 
and Prevention.‘s Differences in patient characteristics 
or laboratory values of the B’-GWGR and B-GPGR 
groups were tested for statistical significance with Yates’ 
corrected x2 for proportions or the non-parametric 
Kruskal-Wallis test for continuous variables. Follow-up 
time was defined from the date of entry into the cohort 
until the occurrence of an AIDS-defining event, or 
patients were censored at the beginning of combined 
ART or on the date of their most recent CD4’ T-cell 
count. Patients were excluded from the current analyses 
if, at the time of entry into the cohort, they had had an 
AIDS-defining condition, primary HIV infection, or 
previous combined ART. The incidence of AIDS- 
defining events was calculated from the number of 
events which occurred per person-year of follow-up for 
all strata. Risk ratios and their 95% confidence intervals 
were calculated using Epi Info (version 6.04~; CDC, 
Atlanta, GA, USA). Adjusted hazard ratios and their 
95% confidence intervals were derived from Cox 
proportional hazards models using STATA software.‘” 
Survival curves for the time to AIDS-defining events 
among the GWGR and GPGR groups were plotted 
using Graph Pad software (version 1.0, Prism, San 
Diego, CA, USA). The log-rank statistic was calculated 
to test for equality of survivor functions. 
RESULTS 
Between October 1987 and December 2000,219 HIV-l- 
infected patients consented to participate in the cohort. 
V3 serotyping was performed for 191 patients: 41(22%) 
patient sera reacted with peptides designed from the 
Brazilian subtype B strain (B’-GWGR motif), 125 (68%) 
samples reacted with peptides designed from the US/ 
European subtype B strain (B-GPGR motif), and for 25 
(11%) samples, serotyping was inconclusive. In 28 (13%) 
subjects, serum samples were not available for V3 sero- 
typing. 
Among the 166 patients in the cohort with definitive 
V3 serology, 42 patients were excluded because they 
had been symptomatic upon entry into the cohort: 40 
presented with AIDS or ARC, and two cases had other 
illnesses which precluded them from entry into the 
analysis. Among the 124 subjects who met the inclusion 
criteria for this analysis, nine had received combined 
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ART before entry into the cohort and were excluded 
from analysis, and one patient had a missing T CD4+ cell 
count at entry. Thus, 114 asymptomatic patients with no 
prior combined ART were included in the analysis. 
The characteristics of the patients included in the 
study are shown in Table 1. Based on V3 serology, 
91 (80%) patients were classified as B-GPGR and 23 
(20%) as B’-GWGR. Proportions of male gender, 
median age, mode of transmission, pretreatment T 
CD4’ count and pretreatment plasma HIV RNA levels 
were not significantly different between the two groups. 
Although the median T CD4’ cell counts at entry 
were not significantly different, a higher proportion of 
patients in the B’-GWGR group had CD4’ counts less 
than 200 cells/mm3. The self-reported route of HIV 
transmission for the sample included 55 (48%) men who 
have sex with men, 40 (36%) individuals who reported 
heterosexual contact, 3 (2%) intravenous drug users 
(IDUs) and 16 (14%) patients who reported unknown 
or no risk factor. PCP prophylaxis was given to all 
patients who presented CD4’ T-cell counts below 200 
cells/mm3, and azidovudine (AZT) or didanosine (DDI) 
monotherapy was given to 37% and 38% of GWGR and 
GPGR individuals in this cohort, respectively. The types 
of AIDS-defining illnesses are shown in Table 1. The 
incidence of AIDS-defining events in the sample was not 
significantly higher among men or among patients less 
than 35 years of age (Table 2). Patients with T CD4’ cell 
counts less than 200 cells/mm3 or 200-400 cells/mm3 
experienced an increased incidence of AIDS-defining 
events (RR: 5.71; 95% CI 1.81-17.9) compared with 
patients who entered the cohort with T CD4’ cell counts 
greater than 400 cells/mm3; (RR: 3.11; 95% CI 1.04- 
9.24). Two AIDS-defining events occurred among 23 
HIV-l-infected subjects with B’-GWGR serology 
during 68.3 person-years of follow-up (both patients had 
CD4+ counts ~200 cells/lJ,L), versus 16 events among 91 
B-GPGR individuals during 232.7 person-years of 
follow-up (3 of 16 had CD4’ counts ~200 cell+L). No 
AIDS-defining events occurred among B’-GWGR 
patients with T CD4’ cell counts above 200 cells/mm3 
at entry, whereas B-GPGR patients with T CD4+ cell 
counts of 200-400 or above 400 cells/mm3 presented six 
and seven AIDS-defining events, respectively. The 
survival times to AIDS-defining events among patients 
with B’-GWGR or B-GPGR serology are shown in 
Table 1. Characteristics at baseline and follow-up of 114 
asymptomatic HIV-l-infected patients 
Characteristics 
GWGR GPGR P 
n=23 (%) n=97 (%) value 
Gender: n (%) 
Female 9 (39) 32 (35) 
Male 14 (61) 59 (65) 
Age: mean years 2 SD 37ta 37+7 
Risk: n (%) 
Homo/bisexual men 11 (48) 44 (48) 
Heterosexual 9 (39) 31 (34) 
Intravenous drug users 0 (0) 3 (3) 
Unknown, others 3 (13) 13 (14) 
T CD4+ cells/mm3 at 
entry: n (%) 
<zoo 7 (30) 9 (IO) 
200-400 5 (22) 31 (34) 
>400 11 (48) 51 (56) 
T CD4+ cells/mm3 
(median ( range) 
Entry 382 (22-1755) 446 (47-441) 
Prior to initiation of 
HAART 241 (30-1021) 297 (29-738) 
Plasma HIV RNA, 
loglo s/mL (median 
+ range) 
Prior to initiation of 
HAART 4.72 (2.5-5.9) 4.6 (1.6-6.08) 
AIDS-defining eventsa 2 (9%) 16 (18%) 
0.9 
1.0 
0.9 
0.04 
0.7 
0.8 
0.9 
0.5 
aAIDS-defining events (according to CDC, 1997) which occurred among 
HIV-l-infected individuals who started as asymptomatic: 
B’-GWGR 1 R carinii pneunomia (PCP) and 1 disseminated herpes zoster 
(more than two dermatomes); B-GPGR: 6 oroesophagus moniliasis; 
4 pulmonary and extrapulmonary tuberculosis; 2 disseminated herpes 
zoster; 1 encephalitis toxoplasmosis, 1 chronic diarrhea by 
Cryptospofidium sp., 1 cerebral cryptococcocis, 1 PCP. 
Table 2. Incidence of AIDS-defining events among 114 initially asymptomatic subjects with seroreactivity to HIV-1 subtype 8 GWGR 
or GPGR peptides 
Varia b/e 
Follow-up time Number incidence ra tel Risk ratio Adjusted hazard 
N (person-years) of events person-year (95% C./J ra tie” (95% C. I.) 
Gender 
Men 
Women 
T CD4 count 
<200 
200-400 
>400 
Me 
<35 
235 
V3 serotype 
GWGR 
GPGR 
73 164.9 14 0.085 2.89 (0.95-8.78) 
41 136.1 a 0.029 Reference 
16 26.9 
36 59.3 
62 214.8 
54 118.8 9 0.076 1.53 (0.61-3.86) 
60 182.2 9 0.049 Reference 
23 68.3 2 0.029 0.43 (0.09-I .85) 
91 232.7 16 0.069 Reference 
5 
6 
0.186 5.71 (1.81-17.9) 
0.101 3.11 (1.04-9.24) 
0.033 Reference 
3.11 (0.93-I 0.35) 
8.29 (2.48-27.69) 
3.80 (1.20-12.02) 
1.45 (0.57-3.65) 
0.16 (0.03-0.93) 
aAdjusted in Cox proportional hazard model for gender, age (~35 years or 235 years), T CD4+ cell count at the time of entry into the cohort (<200, 
200-400, 2400 cells/mm3) and variant of HIV-1 subtype B. 
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Figure 1. Time to AIDS-defining events prior to antiretroviral 
therapy for 114 asymptomatic patients infected with GPGR or 
GWGR variants of HIV-1 subtype B. 
Figure 1. In a proportional hazard model including age, 
gender, T CD4+ cell count at entry into the cohort, and 
V3 serology, B’-GWGR serology was associated with 
decreased hazard for presenting an AIDS-defining 
condition during follow-up (adjusted hazard ratio 
0.16; 95% CI 0.03- 0.93), while patients with decreased 
T CD4+ cell counts at entry were at increased risk (Table 
2). During follow-up, three patients in the sample with 
B-GPGR serology died after experiencing an AIDS- 
defining event. None of the patients with B’-GWGR 
serology died during follow-up. 
The B’-GWGR patients experienced only two 
AIDS-defining events, despite 68.3 person-years of 
follow up. If the rate of progression to AIDS-defining 
events for the B’-GWGR group been equal to that of 
the B-GPGR group (0.069 events/person-years), we 
would have expected five AIDS-defining events in the 
B’-GWGR group during the follow-up time. 
DISCUSSION 
The present study suggests that HIV-l infected patients 
with seroreactivity to the Brazilian subtype B variant (B’- 
GWGR) have a decreased rate of progression to an 
AIDS-defining illness compared to those with B-GPGR 
serology. This decreased risk was found to be independent 
of T CD4+ cell count in a proportional hazards model. T 
CD4+ cell count was the most important predictor of 
disease progression in univariate analyses. Although a 
small number of AIDS-defining events were observed in 
patients with B’-GWGR serology, the observation of 
different rates per person-year of follow-up time after 
adjusting for T CD4’ cell count suggests that there is a 
biological difference between the infecting subtypes. 
The current study reinforces the findings of an in- 
vestigation of clinical outcomes in patients with subtype 
B’-GWGR or B-GPGR serology in a cohort of HIV-l- 
infected individuals in Rio de Janeiro, Brazil.“j Among 
321 patients in the cohort from Rio, 32% of B-GPGR- 
reactive individuals versus 22% of B’-GWGR-reactive 
patients developed AIDS-defining events, and the B’- 
GWGR group had decreased risk of progression to 
AIDS-defining events in a proportional hazards model 
including age and mode of acquisition of HIV.i6 These 
investigators included follow-up time when ART was 
received, because the proportion of patients in each 
group who received ART did not differ. In the present 
study, follow-up time after the initiation of ART was not 
included in the analysis, because the hazard of AIDS- 
defining events is influenced by therapy. In the present 
cohort in Sao Paulo, V3 serology was not found to be 
associated with younger age, in contrast with the cohort 
in Rio de Janeiro, in which younger patients showed 
more B-GPGR reactivity and a higher proportion of 
AIDS-defining events. l6 Although the consistency of the 
findings from these two studies in Brazil supports the 
hypothesis of a direct effect of the subtype B variant 
(B’-GWGR), the possibility exists that an as-yet un- 
identified cofactor accounts for the observed differences. 
The current study did not have adequate power to in- 
vestigate additional risk factors for disease progression. 
Fortunately, patients infected with either B’-GWGR 
or B-GPGR strains showed similar responses to anti- 
HIV therapy after the initiation of treatment, once ART 
became available in Brazil and the patients decided 
to begin therapy (data not shown). This demonstrates 
that reverse transcriptase (RT) and protease genes are 
conserved, allowing for a good response. Even greater 
genetic divergence than that between these two subtype 
B strains, such as that between subtypes B and C, was 
not shown to influence either the natural history or the 
response to HAART in a report from Israel.20 
We do not have an explanation for the decreased 
pathogenicity of the B’-GWGR V3 serotype. It has 
been shown that some HIV subtypes, such as subtype 
D, possess greater ability to induce sincitia, indicating 
a more aggressive biological phenotype.21 One good 
example of how changes in viral structure may interfere 
with pathogenesis is the HIV strain with a deleted nef 
gene.’ However, this strain was passed to several 
individuals through unscreened blood transfusion, and 
did not encounter host mucosal immunity, suggesting 
that it has not emerged following viral adaptation and 
selection. In patients infected with this strain, in spite of 
more a stable trend than in individuals infected with 
wild-type HIV-l virus, T CD4’ cell count has been 
decreasing, showing that nef- HIV-l is not completely 
attenuated but may show a different rate of progression 
to disease in long-term follow-up.22 
In contrast, the Brazilian subtype B variant (B’- 
GWGR motif) is widely disseminated and passed 
through several modes of transmission. The possibility 
that subtype B variant GWGR emerged recently from 
a viral adaptation of the GPGR motif is highly im- 
probable, since mutations causing amino acid changes 
are rare. Intermediary mutation in the tip of V3 loop, 
such as CCA to TGG, has hardly ever been described in 
Brazil (or only once. ). 3 23 Therefore, the B’-GWGR strain 
has been subjected to selective pressures to be main- 
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tained as an important strain in Brazil. It may be 
evidence of a founder effect rather than a better viral 
adaptation. However, if the Brazilian B’-GWGR variant 
has been less virulent than the US/European strain 
B-GPGR, this may represent improved selection for 
dissemination, and we would expect its prevalence 
among HIV-l-infected individuals in Brazil to increase 
through time. In addition, some countries close to Brazil, 
such as Bolivia and Chile, have reported 10% pre- 
valence of the B’-GWGR strain, indicating either a 
connection with the Brazilian epidemic or later intro- 
duction of the variant into the population.24,25 In 
Trinidad and Tobago, a different subtype B variant strain 
with a unique signature in the V3 loop, deletion of one 
threonine just C-terminal of the crown of the loop, has 
been present without increasing in prevalence since the 
beginning of the HIV-l epidemic.26 
One source of misclassification in the present study 
could be that the EIA with synthetic peptides is not able 
to distinguish all of the V3 diversity in Brazil. In fact, 
HIV-l isolates have shown extensive variability in the V3 
region. For this reason, we have only analyzed samples 
with distinct GWGR/GPGR serologic profiles. Also, 
subtype F infections may account for some GPGR 
reactivity, but subtype F represents less than 10% of 
HIV-l infections in S2o Paulo, and the GWGR motif has 
not been identified in the V3 region of subtype F strains.5 
The GWGR/GPGR serology was observed to be 
stable in the same patient over time in repeated assays 
performed during this investigation. One hypothesis had 
been that the presence of quasi-species could interfere 
with the ability of the EIA to distinguish the Brazilian 
subtype B variant (B’-GWGR) from the US/European 
variant. We noted that individual patients maintained 
GWGR seroreactivity over time, and serial serum 
samples did not bind to B-GPGR synthetic peptides 
(data not shown). In fact, HIV-l subtype B quasi-species 
in a naive population appear to evolve though unbiased 
expansion around a stationary consensus sequence. This 
indicates that the sampling moment, relative to the 
seroconversion data, will not greatly influence the results 
of phylogenetic analysis.27 
A biological explanation is needed for the observed 
decreased pathogenesis of the Brazilian variant subtype 
B strain with the GWGR motif when compared to 
that with the GPGR motif in the V3 loop region. The 
influence of these amino acid substitutions in the viral 
envelope upon clinical outcomes may be a model for 
investigating the role of the envelope in the natural 
history of HIV infection. 
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